Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Impact · against what's priced in

The article provides no material catalysts for Amgen or McKesson, as the reported revenue growth and distribution relationships are already fully reflected in their current valuations. Bristol Myers Squibb is highlighted as a value-oriented income play, but the lack of growth confirms the market's current stagnant valuation.

MCK+0.00

Already priced in

The price assumes

GLP-1 distribution growth at 24% YoY